Transgene News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

16.03.23	Transgene: 2022 Full-year Results and Business Update (Businesswire)
15.03.23	Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023 (Businesswire)
09.03.23	Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors (Businesswire)
06.01.23	Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration (Businesswire)
04.01.23	Transgene Announces Financial Calendar for 2023 (Businesswire)
15.12.22	Transgene Announces Upcoming Investor Meetings (Businesswire)
14.11.22	Transgene and BioInvent Joint Paper on BT-001 Wins JITC "Best Oncolytic and Local Immunotherapy Paper” Award for 2022 (Businesswire)
07.11.22	Transgene Reports Business Update And Q3 2022 Financial Position (Businesswire)
02.11.22	Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers (Businesswire)
27.09.22	R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data (Businesswire)
12.09.22	Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022 (Businesswire)
07.09.22	Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022 (Businesswire)
31.08.22	Transgene Announces Upcoming Investor Meetings (Businesswire)
28.06.22	Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA® (Businesswire)
27.06.22	Transgene and BioInvent Announce Positive Progress for BT-001 (Businesswire)
06.06.22	Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022 (Businesswire)
27.05.22	Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022 (Businesswire)
25.05.22	Transgene’s Combined General Meeting of May 25, 2022 (Businesswire)
17.05.22	Transgene Announces Upcoming Investor Meetings (Businesswire)
10.05.22	Transgene: Q1 2022 Financial Position and Business Update (Businesswire)
08.04.22	Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050 (Businesswire)
06.04.22	Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022 (Businesswire)
31.03.22	Transgene’s Board of Directors Strengthens Its Governance and Proposes the Appointment of Dr. Alessandro Riva as Independent Chairman (Businesswire)
16.03.22	Transgene Confirms the Potential of Its Two Innovative Platforms and Expects Significant Clinical Results in 2022 (Businesswire)
09.03.22	Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022 (Businesswire)
09.03.22	Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022 (Businesswire)
10.02.22	Transgene Appoints Steven Bloom as Chief Business Officer (Businesswire)
20.01.22	Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade (Businesswire)
18.01.22	Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors (Businesswire)
06.01.22	Transgene Announces Financial Calendar for 2022 (Businesswire)
17.12.21	Transgene Announces Investor Meetings for January 2022 (Businesswire)
15.12.21	Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform (Businesswire)
28.06.21	First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy (Businesswire)
24.06.21	Transgene: First Patient Enrolled in Expanded Phase II Clinical Trial of TG4001 + Avelumab Vs Avelumab Alone in Patients With HPV16-positive Anogenital Cancers (Businesswire)
08.06.21	Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs) (Businesswire)
26.05.21	Transgene: Combined General Meeting of May 26, 2021 (Businesswire)
27.04.21	Transgene Reports Business Update and End Q1 2021 Financial Position (Businesswire)
12.04.21	Transgene Announces Upcoming Investor Meetings (Businesswire)
09.04.21	Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses (Businesswire)
07.04.21	Transgene: Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021 (Businesswire)
10.03.21	Transgene: Significant Milestones Achieved on All Drug Candidates in 2020 and Financial Visibility until 2022 (Businesswire)
10.03.21	Transgene Expands Phase II Clinical Trial of Therapeutic Vaccine TG4001 in Combination With Avelumab Versus Avelumab Monotherapy in Patients With HPV16-positive Anogenital Cancers (Businesswire)
02.03.21	Transgene to Present Its Immuno-Oncology Expertise at Upcoming Scientific Conferences (Businesswire)
01.03.21	Transgene and BioInvent Have Enrolled First Patient in Phase I/IIa Trial of Novel Oncolytic Virus BT-001 in Solid Tumors (Businesswire)
21.01.21	First Head & Neck Cancer Patient Treated in France in a Phase I Trial With TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy (Businesswire)
19.01.21	Transgene and BioInvent Receive Approval From ANSM to Proceed With Phase I/IIa Trial of Anti-CTLA4-armed Oncolytic Virus BT-001 in Solid Tumors (Businesswire)
14.01.21	Transgene Appoints Gaëlle Stadtler as Director of Human Resources (Businesswire)
21.12.20	Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors (Businesswire)
17.12.20	Transgene Announces Financial Calendar for 2021 (Businesswire)
16.12.20	Transgene Announces Investor Meetings for January 2021 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Transgene S.A.

Aktien Top/Flop

Meistgelesene Nachrichten